Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
Cyclo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- shareholders
- Rules
- 5620(a), 5810(c)(2)(G)
Exact text from the filing
January 10, 2025, Cyclo Therapeutics, Inc. (the "Company”) received a letter from The Nasdaq Stock Market ("Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Cyclo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- shareholders
- Rules
- 5620(a), 5810(c)(2)(G)
Exact text from the filing
January 10, 2025, Cyclo Therapeutics, Inc. (the "Company”) received a letter from The Nasdaq Stock Market ("Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for continued listing because it had not yet held an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. Pursuant to the Nasdaq Listing Rules, the Company has 45 calendar days (until February 24, 2025) to submit a plan to regain compliance with the Nasdaq Listing Rules, and if the plan is accepted, Nasdaq may grant the Company an excepti
View on SEC.gov